Skip to main content

Month: March 2024

Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules

NEW YORK, NY, March 27, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — Applied UV, Inc. (NASDAQ: AUVI; AUVIP) (“Applied UV” or the “Company”), a leader in smart building technology solutions, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of common stock of the Company (“Common Stock”) and pre-funded warrants (“Pre-Funded Warrants”) in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investors, common warrants (“Common Warrants”). Aggregate gross proceeds to the Company from both transactions are expected to be approximately $2.76 million, the maximum availability under the effective shelf registration statement. The transactions consist of (i) the public sale of an aggregate of 1,726,875 shares of...

Continue reading

Soitec confirms guidance for FY’24 and publishes its outlook for FY’25

Soitec confirms guidance for FY’24 and publishes its outlook for FY’25 Bernin (Grenoble), France, March 27th, 2024 – Soitec (Euronext Paris), a world leader in designing and manufacturing innovative semiconductor materials, today confirms its guidance for the fiscal year 2024 (ending on March 31st, 2024) and provides some preliminary indications about its prospects for the fiscal year 2025 (ending on March 31st, 2025). FY’24 guidance Soitec confirms that it expects revenue for FY’24 to decline by around 10% at constant exchange rates and perimeter and an EBITDA1 margin2 for FY’24 of around 34%, in line with the guidance given on February 7th, 2024. FY’24 results will be published on May 22nd, 2024. FY’25 outlook Looking ahead, Soitec continues to anticipate significant growth in its three end-markets, where it is strengthening its...

Continue reading

Changes to the Soitec Board of Directors

Changes to the Soitec Board of Directors Bernin (Grenoble), France – 27 March 2024 – At its meeting today, the Soitec Board of Directors took note of Eric Meurice’s decision not to seek renewal of his mandate as Director at the next Annual General Meeting of shareholders on 23 July 2024. At that date, Eric Meurice will step down as a Director and as Chairman of the Board. He will take on the role of strategic advisory to the Chief Executive Officer for a period of one year. All members of the Board expressed their gratitude to Eric Meurice for his unfailing commitment to Soitec over the past six years and for his major contribution to the work of the Board, which has enabled Soitec to create value for all its stakeholders. Eric Meurice will continue in office until 23 July 2024 and will ensure a smooth handover to his successor....

Continue reading

Vranken-Pommery Monopole – ANNUAL RESULTS 2023 – Operating income up 12.7% to €39 million

ANNUAL RESULTS 2023Operating income up 12.7% to €39 millionCONSOLIDATED TURNOVER     CURRENT OPERATING INCOME   EQUITY   NET FINANCIAL DEBT  (excluding IFRS 16)  € 338 million   € 39 million   € 420 million   € 635 million    +1,2%     +12,7%     +2,5%     +1,4%        (vs 2022)      +3,9 €M   +4,4 €M   +10,1 €M   +9 €M                       Reims, March 27, 2024 The Board of Directors of Vranken-Pommery Monopole met on March 27, 2024 under the chairmanship of Mr. Paul-François Vranken, and in the presence of the Statutory Auditors, to approve the Group’s financial statements for the year 2023. ResultsConsolidated data in €M 31/12/2023...

Continue reading

Tarkett- AVAILABILITY OF THE 2023 UNIVERSAL REGISTRATION DOCUMENT

AVAILABILITY OF THE 2023 UNIVERSAL REGISTRATION DOCUMENT Paris, March 27, 2024 — Tarkett informs that it has filed its 2023 Universal Registration Document with the Autorité des Marchés Financiers (AMF) on March 27, 2024. The 2023 Universal Registration Document, which includes the 2023 Annual Financial Report, includes in particular:the Management Board report; the Supervisory Board Report on Corporate Governance; the Extra-Financial Performance Declaration; the Statutory Auditors reports and the information related to their fees; the share buyback program description; and the agenda and draft resolutions of the Combined Shareholder’s Meeting to be held on April 26, 2024.This Document is made available to the public, free of charge under the conditions provided by applicable regulations and may be consulted on the “Investors” page...

Continue reading

HighCo: 2023 annual earnings

Aix-en-Provence, 27 March 2024 (6 p.m.) HIGHCO: GOOD FINANCIAL RESULTS IN 2023 (22.1% OPERATING MARGIN AND EPS OF €0.55) TO TACKLE A MORE CHALLENGING YEAR IN 2024; PROPOSED DIVIDEND OF €0.20 PER SHARE Business decline in 20232023 gross profit of €74.35 m, down 2.7% LFL1. Digital businesses holding up well (up 1.2% LFL) and strong decline in offline businesses (down 10.6% LFL). Drop in business in France (down 3% LFL) and less significant decline in International business (down 0.6% LFL), with Belgium holding up well.Sharp rise in profitability and in EPSHeadline PBIT2 of €16.41 m, up 4.2%. Operating margin2 of 22.1%, with a sharp increase of 150 basis points. Recurring operating income of €15.85 m, up 8%. Adjusted attributable net income3 of €10.9 m, with a sharp rise of 20.9%. Adjusted earnings per share (EPS)3 of €0.55, for a...

Continue reading

Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy

PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) — Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies. The acquisition by Indegene Ireland, a subsidiary of Indegene Limited, augments Indegene’s depth of clinical and regulatory writing expertise for market authorization applications globally. Trilogy Writing & Consulting is a Germany, UK, and US-based, medical writing consultancy with know-how in the development and delivery of clinical, regulatory, safety, and medical content. It applies its expertise and unique approaches to deliver quality medical writing output....

Continue reading

ARGAN delivered a 4,600 sq.m, Aut0nom®-labelled distribution centre to DSV in Normandie

Press release – Neuilly-sur-Seine, Wednesday, March 27, 2024 – 5.45 pm ARGAN delivered a 4,600 sq.m, Aut0nom® -labelled distribution centre to DSV in Normandie Photo credit: Argan After works that lasted for 10 months, DSV Road teams are now operating on the new distribution platform located in Eslettes (76), near Rouen. This 4,600 sq.m building, which was developed by ARGAN, is Aut0nom®-labelled, i.e. an “in-use Net Carbon Zero warehouse”. DSV is operating this platform through its DSV Road division, as part of a nine-year fixed-term lease. This is the second time that DSV and ARGAN – which already owns the Gennevilliers buildings where the DSV French headquarters are located – work together. DSV is a front-running international company, which delivers transportation and logistics services. Aut0nom®, an in-use Carbon Zero site A particular...

Continue reading

Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer

Strasbourg, France, March 27, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of Lucie Larguier as Chief Financial Officer (CFO), effective immediately. Formerly VP, Corporate Communication and Investor Relations at Transgene, in her new role as CFO, Lucie Larguier will be responsible for all aspects of the Company’s financial strategy, management and operations to ensure efficient delivery of Transgene’s innovative immunotherapy pipeline. Lucie succeeds Arnaud Dubarry who has stepped down to pursue other opportunities. Already a member of the executive management committee, Lucie Larguier brings a comprehensive, cross-functional view of the Company’s operations and finances as well as a deep...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.